Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Consortium to tackle PTSD
October 2019
SHARING OPTIONS:

GENEVA—Addex Therapeutics has announced plans to lead a consortium that will focus on developing small-molecule negative allosteric modulators (NAMs) that target the metabotropic glutamate receptor 7 (mGlu7) as a possible treatment for the reduction of fear memory in post-traumatic stress disorder (PTSD). In addition to Addex, participants include Naason Science, Endotherm, Nucro Technics and Radboud University. Eurostars has awarded the consortium, DiSARM FEAR, a €4.85-million grant to fund the research. The goal is to have novel mGlu7 NAMs ready to begin IND-enabling studies within three years.
 
“This Eurostars grant is a significant validation of the pioneering discovery work we have been doing in the field of mGlu7 and in particular the field of PTSD, a significant and growing unmet medical need,” said Robert Lütjens, head of Discovery Biology at Addex.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.